AR102202A1 - Compuestos de oxazol y su uso como inhibidores de bace de oxazol - Google Patents
Compuestos de oxazol y su uso como inhibidores de bace de oxazolInfo
- Publication number
- AR102202A1 AR102202A1 ARP150103240A ARP150103240A AR102202A1 AR 102202 A1 AR102202 A1 AR 102202A1 AR P150103240 A ARP150103240 A AR P150103240A AR P150103240 A ARP150103240 A AR P150103240A AR 102202 A1 AR102202 A1 AR 102202A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- optionally substituted
- dementia
- proviso
- alzheimer
- Prior art date
Links
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 abstract 2
- 241000720974 Protium Species 0.000 abstract 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 229910052722 tritium Inorganic materials 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010036631 Presenile dementia Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos de fórmula (1), (2), ó (3) y sus composiciones o preparados farmacéuticos. También, métodos para tratar o prevenir patologías relacionadas con el bA tales como el síndrome de Down, angiopatía b-amiloide tal como, pero de manera no taxativa, angiopatía amiloide cerebral o hemorragia cerebral hereditaria, trastornos asociados con deficiencias cognitivas tales como, pero de manera no taxativa, MCI (deficiencia cognitiva leve), enfermedad de Alzheimer, pérdida de memoria, síntomas de déficit de atención asociado con la enfermedad de Alzheimer, neurodegeneración asociada con enfermedades tales como enfermedad de Alzheimer o demencia, incluyendo demencia de origen mixto vascular y degenerativo, demencia pre-senil, demencia senil y demencia asociada con la enfermedad de Parkinson. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o un profármaco del mismo, o una sal aceptable farmacéuticamente del compuesto de fórmula (1) o su profármaco, donde: A representa O, CH₂, CH₂CH₂, S, o SO₂; X, Y, Z, y W cada uno en forma independiente representa N o CR¹; n es 0 ó 1; R¹, en forma independiente para cada caso, se selecciona entre hidrógeno, halógeno, CN, y alquilo, alquenilo, alquinilo, alcoxi, arilo, heteroarilo, u oxima opcionalmente sustituidos; R² y R³ se seleccionan en forma independiente entre protio, deuterio, tritio, y alquilo opcionalmente sustituido, con la salvedad de que cuando n es 1, R² y R³ se seleccionan en forma independiente entre protio, deuterio, y tritio; y R⁶ y R⁷ se seleccionan en forma independiente entre hidrógeno, halógeno, y alquilo opcionalmente sustituido, alcoxialquilo, cicloalquilo, o heterocicloalquilo, con la salvedad de que R⁶ y R⁷ no son simultáneamente hidrógeno, y con la salvedad adicional de que cuando A es CH₂CH₂ y n es 0, R⁶ y R⁷ no son simultáneamente alquilo inferior; o R⁶ y R⁷ junto con el carbono al cual están unidos, forman un anillo carbocíclico o heterocíclico opcionalmente sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060752P | 2014-10-07 | 2014-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102202A1 true AR102202A1 (es) | 2017-02-08 |
Family
ID=55652644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103240A AR102202A1 (es) | 2014-10-07 | 2015-10-07 | Compuestos de oxazol y su uso como inhibidores de bace de oxazol |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10053453B2 (es) |
| AR (1) | AR102202A1 (es) |
| TW (1) | TW201629025A (es) |
| UY (1) | UY36347A (es) |
| WO (1) | WO2016055858A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122268A1 (en) | 2017-12-21 | 2019-06-27 | Astrazeneca Ab | Processes for the stereoselective preparation of bace inhibitors |
| WO2019122421A1 (en) | 2017-12-22 | 2019-06-27 | Astrazeneca Ab | Stereoselective ketone reduction using a ketoreductase enzyme |
| WO2019129755A1 (en) | 2017-12-29 | 2019-07-04 | Astrazeneca Ab | Ketal hydrogenation |
| WO2019129750A1 (en) | 2017-12-29 | 2019-07-04 | Astrazeneca Ab | Processes for the racemization of dihydroimidazole ring systems |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009064418A1 (en) * | 2007-11-14 | 2009-05-22 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| AR075854A1 (es) * | 2009-03-13 | 2011-05-04 | Vitae Pharmaceuticals Inc | Inhibidores de beta- secretasa |
| US20120065195A1 (en) | 2010-03-31 | 2012-03-15 | Clark Christopher T | Compounds for treating neurodegenerative diseases |
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US9079919B2 (en) * | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
| TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β－分泌酶抑制劑 |
| WO2013181202A2 (en) | 2012-05-30 | 2013-12-05 | Astellas Pharma Inc. | Chromane compounds |
| US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
| US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
| US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
| US10548882B2 (en) | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
-
2015
- 2015-10-07 AR ARP150103240A patent/AR102202A1/es unknown
- 2015-10-07 WO PCT/IB2015/002101 patent/WO2016055858A1/en active Application Filing
- 2015-10-07 US US15/516,848 patent/US10053453B2/en active Active
- 2015-10-07 TW TW104133098A patent/TW201629025A/zh unknown
- 2015-10-07 UY UY0001036347A patent/UY36347A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016055858A1 (en) | 2016-04-14 |
| US10053453B2 (en) | 2018-08-21 |
| US20170313686A1 (en) | 2017-11-02 |
| TW201629025A (zh) | 2016-08-16 |
| UY36347A (es) | 2016-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099785A1 (es) | Compuestos heteroarilos y su uso como medicamentos | |
| TR201904658T4 (tr) | Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları. | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| CU20160167A7 (es) | Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| PH12016501791B1 (en) | Muscarinic receptor agonists | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| PE20190337A1 (es) | NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| CL2015000717A1 (es) | Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c. | |
| CY2023001I2 (el) | 2,4,6-τριφθορο-ν-[6-(1-μεθυλο-πιπεριδινο-4-καρβονυλο)-πυριδιν-2-υλο]-βενζαμιδιο για την αντιμετωπιση ημικρανιας μεσω της στοματικης ή της ενδοφλεβιας οδου | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| MX2016012451A (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina. | |
| AR102202A1 (es) | Compuestos de oxazol y su uso como inhibidores de bace de oxazol | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| AR077365A1 (es) | Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta | |
| AR104262A1 (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas | |
| TR201904639T4 (tr) | Muskarinik M1 reseptörü pozitif allosterik modülatörler. | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| AR091731A1 (es) | Antagonistas del receptor de mineralocorticoides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |